Interaction of liposomes bearing a lipophilic doxorubicin prodrug with tumor cells
When used as nanosized carriers, liposomes enable targeted delivery and decrease systemic toxicity of antitumor agents significantly. However, slow unloading of liposomes inside cells diminishes the treatment efficiency. The problem could be overcome by the adoption of lipophilic prodrugs tailored for incorporation into lipid bilayer of liposomes. We prepared liposomes of egg yolk phosphatidylcholine and yeast phosphatidylinositol bearing a diglyceride conjugate of an antitumor antibiotic doxorubicin (a lipophilic prodrug, DOX-DG) in the membrane to study how these formulations interact with tumor cells. We also prepared liposomes of rigid bilayer-forming lipids, such as a mixture of dipalmitoylphosphatidylcholine and cholesterol, bearing DOX in the inner water volume, both pegylated (with polyethylene glycol (PEG) chains exposed to water phase) and non-pegylated. Efficiency of binding of free and liposomal doxorubicin with tumor cells was evaluated in vitro using spectrofluorimetry of cell extracts and flow cytometry. Intracellular traffic of the formulations was investigated by confocal microscopy; co-localization of DOX fluorescence with organelle trackers was estimated. All liposomal formulations of DOX were shown to distribute to organelles retarding its transport to nucleus. Intracellular distribution of liposomal DOX depended on liposome structure and pegylation. We conclude that the most probable mechanism of the lipophilic prodrug penetration into a cell is liposome-mediated endosomal pathway.
Keywordsliposomes drug delivery doxorubicin lipophilic prodrugs cell organelles intracellular traffic
Unable to display preview. Download preview PDF.
- 7.Vodovozova E.L., Kuznetsova N.R., Kadykov V.A., Khutsyan S.S., Gaenko G.P., Molotkovskii J.G. 2008. Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate. Ros. nanotekhonologii (Rus.). 3(3–4), 162–172 [Transl. version in Nanotechnologies in Russia. 3 (3–4), 228–239].Google Scholar
- 8.Kuznetsova N., Kandyba A., Vostrov I., Kadykov V., Gaenko G., Molotkovsky J., Vodovozova E. 2009. Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles. J. Drug Deliv. Sci. Technol. 19, 51–59.Google Scholar
- 9.Kozlov A.M., Korchagina E.Yu., Vodovozova E.L., Bovin N.V., Molotkovskii Yu.G., Syrkin A.B. 1997. Enhancement of antitumor activity of sarcolysin by its transformation to lipid derivative and incorporation into membrane of liposomes equipped with a carbohydrate targeting ligand. Bull. eksperim. biol. med. (Rus.). 123, 439–441.CrossRefGoogle Scholar
- 11.Vodovozova E.L., Moiseeva E.V., Gaenko G.P., Bovin N.V., Molotkovskii Yu.G. 2008. Application of lipidconjugated chemotherapeutics in liposomes as a method to enhance anticancer effect of the drugs. Ros. bioterapevt. zhurn. (Rus.). 7(2), 24–33.Google Scholar
- 18.Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. 2010. Complement activation cascade triggered by PEG#PL engineered nanomedicines and carbon nanotubes: The challenges ahead. J. Control. Release. 146, 175–181.PubMedCrossRefGoogle Scholar